$3.47
+0.04 (+1.17%)
Open$3.43
Previous Close$3.43
Day High$3.67
Day Low$3.43
52W High$6.93
52W Low$1.87
Volume—
Avg Volume86.2K
Market Cap26.24M
P/E Ratio—
EPS$-5.31
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,145.0% upside
Current
$3.47
$3.47
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 147.7K | 1.69M | 1.69M |
| Net Income | -26,071,758 | 118.4K | 113.8K |
| Profit Margin | -17,634.9% | 7.0% | 6.8% |
| EBITDA | -28,889,204 | 180.1K | 185.2K |
| Free Cash Flow | — | 113.7K | 84.7K |
| Rev Growth | — | -7.6% | +15.2% |
| Debt/Equity | 0.09 | 0.66 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |